To ascertain the potential clinical relevance for the use of PRIMA-1MET in GBM, and because of the important role of GSCs as a disease reservoir in GBM [87], we used patient-derived GSCs with different levels of MGMT and p53 status. This evidence concerns the gene MGMT and glioblastoma.